Amer Zeidan: Can Early Blood Count Changes Predict Imetelstat Response in Lower Risk MDS?
Amer Zeidan, Chief, Division of Hematologic Malignancies; Professor of Medicine at Yale University, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in Blood Cancer Journal, adding:
“Our newest paper on association between early neutropenia and thrombocytopenia with subsequent clinical response to imetelstat in lower risk MDS.”
Title: Association between treatment-emergent cytopenias and clinical responses to imetelstat in lower-risk myelodysplastic syndromes
Authors: Amer M. Zeidan, Valeria Santini, María Díez-Campelo, Michael R. Savona, Mikkael A. Sekeres, Yazan F. Madanat, Pierre Fenaux, Azra Raza, Moshe Mittelman, Sylvain Thépot, Rena Buckstein, Ulrich Germing, David Valcárcel, Anna Jonášová, Sheetal Shah, Qi Xia, Libo Sun, Shyamala Navada, Tymara Berry, Uwe Platzbecker and Rami S. Komrokji
Stay updated on all scientific advances Hemostasis Today.
-
Jul 21, 2026, 21:12Ammar Al Awawdeh: Bridging the Hemostatic Gap – Functional Platelet Salvage in CPB
-
Jul 21, 2026, 19:44Shinya Goto: JCS/JPCPHS 2025 Guideline Now Available in English
-
Jul 21, 2026, 19:43Abdul Mannan: Why Is HbS or HbD Approximately 40% in Heterozygotes Rather Than 50%?
-
Jul 21, 2026, 19:42Haemophilia Maintains a 2025 Impact Factor of 3.0 – WFH
-
Jul 21, 2026, 19:41Wolfgang Miesbach: SR604 Restores Thrombin Generation Where It Is Needed
-
Jul 21, 2026, 19:40Filmon Tesfay: Our New Case Report on Cerebral Venous Thrombosis Is Now Published
-
Jul 21, 2026, 15:02Sham Zamil: The Role of ABO Compatibility in Platelet Pooling
-
Jul 21, 2026, 13:43Dima Shulkin: Assessing AI-Driven Blood Test Screening for Colorectal Cancer
-
Jul 21, 2026, 13:24Benoit Mores: National Initiative Targets Better Cardiovascular Outcomes